Interplay between BET Proteins and the Pre-Replication Complex Unveils Therapeutic Vulnerabilities in Cancer
Doberstein, K.; Messner, V.; Berlit, S.; Tuschy, B.; Suetterlin, M.; Marme, F.
Show abstract
Replication stress is a critical event in cancer development and understanding the underlying molecular mechanisms can help to identify new treatment strategies. Here, we investigate the molecular interplay between the pre-replication complex (pre-RC) and the bromodomain and extraterminal domain (BET) proteins in orchestrating replication stress response. Our findings reveal a mutual dependency between BET proteins and the pre-RC within cancer cells. Notably, reduction in origin licensing or replication initiation makes cells more susceptible to the BET-inhibitor AZD5153. Furthermore, we observe synergistic effects when combining the CDC7 inhibitor XL413 with AZD5153, effects which were partly dependent on TP53 mutation status. This combination treatment results in unresolved DNA damage and R-loop formation, leading to increased genomic instability. These insights pave the way for novel strategies for targeted cancer therapies and provide a foundation for further investigation into the interplay between CDC7 and BET proteins in replication stress response. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=194 SRC="FIGDIR/small/645172v2_ufig1.gif" ALT="Figure 1"> View larger version (85K): org.highwire.dtl.DTLVardef@f5b170org.highwire.dtl.DTLVardef@545fbeorg.highwire.dtl.DTLVardef@159b631org.highwire.dtl.DTLVardef@c851cf_HPS_FORMAT_FIGEXP M_FIG C_FIG The graphic illustrates how the CDC7 inhibitor XL413 and the BET inhibitor AZD5153 work together in TP53-deficient cancer cells. First, XL413 prevents activation of the origin of replication complex, leading to DNA damage. Second, the DNA repair machinery is unable to resolve this damage, resulting in the accumulation of unresolved R-loops and genomic instability. Ultimately, this cascade culminates in cell death.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Genome-wide CRISPR screen identifies KEAP1 perturbation as a vulnerability of ARID1A-deficient cells 95%
- The epithelial-mesenchymal transcription factor SNAI1 represses transcription of the tumor suppressor miRNA let-7 in cancer 94%
- The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma 94%
Similar papers in this journal
- The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma 96%
- The anti-tumor effect of trifluridine via induction of aberrant mitosis is unaffected by mutations modulating p53 activity 94%
- Inhibiting BCKDK in triple-negative breast cancer suppress protein translation, impair mitochondrial function, and potentiate doxorubicin cytotoxicity 94%
Similar papers in this journal
- The most common RNF43 mutant G659Vfs41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis 95%
- PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma 95%
- Periostin facilitates ovarian cancer recurrence by enhancing cancer stemness 94%
Similar papers in this journal
- The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities. 96%
- Inhibition of tryptophan-2,3-dioxygenase impairs DNA damage tolerance and repair in glioma cells 94%
- DNA replication during acute MEK inhibition drives acquisition of resistance through amplification of the BRAF oncogene 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.